MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

ZTS · NYSE

Zoetis Inc. Class A

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$77.51As of Jul 28, 2026
Market capitalization$32.49B
52-week range$71.47–$160.48
S&P 500 portfolio weight0.05%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$85.00+9.7% vs. reference
Average$99.38+28.2% vs. reference
High$130.00+67.7% vs. reference
6 Buy6 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 6, 2026Jun 2026
Consensus EPS$1.848 estimates
Expected range$1.77–$1.89Low to high EPS
Dec 2026$6.87Street EPS consensus
Dec 2027$7.35Street EPS consensus
Dec 2028$7.85Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+2.3% YoY$9.47B$9.26B
Operating income$3.55B$3.34B
Net income$2.67B$2.49B
Operating cash flow$2.9B$2.95B
Capital expenditures($0.62B)($0.66B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Zoetis (ZTS) Beats Stock Market Upswing: What Investors Need to Know

BNK Invest

Friday's ETF with Unusual Volume: FTXH

Zacks

Zoetis (ZTS) Stock Dips While Market Gains: Key Facts

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.